Literature DB >> 19830400

[Carotid stenosis: is the distinction between "symptomatic" and "asymptomatic" obsolete?].

A Chatzikonstantinou1, M G Hennerici.   

Abstract

Carotid stenosis is common, especially among patients with vascular risk factors. The usual distinction between "symptomatic" and "asymptomatic" corresponds to older studies on the surgical vs. conservative treatment and to newer studies on interventional treatment (angioplasty with/without stent vs. surgery). However, both forms only describe different stages of activity of the same disease. They are markers of a systemic atherosclerosis, which results in a high risk of cardiovascular events in particular. All patients with carotid stenosis profit from regular clinical and duplexsonographic follow-up-studies of the brain arteries, cardiovascular assessment and good control of all vascular risk factors. Patients with carotid stenosis may profit from carotid intervention, if this takes place shortly after onset of associated cerebral ischemia and/or if there is a favorable benefit-risk ratio.

Entities:  

Mesh:

Year:  2009        PMID: 19830400     DOI: 10.1007/s00108-009-2468-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)

Authors: 
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

2.  Successful carotid endarterectomy for cerebrovascular insufficiency. Nineteen-year follow-up.

Authors:  M E DeBakey
Journal:  JAMA       Date:  1975-09-08       Impact factor: 56.272

3.  Outcome in patients with asymptomatic neck bruits.

Authors:  B R Chambers; J W Norris
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

4.  High intensity transient signals (HITS) in patients with carotid artery disease.

Authors:  S Ries; U Schminke; M Daffertshofer; M Hennerici
Journal:  Eur J Med Res       Date:  1996-04-18       Impact factor: 2.175

5.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

6.  Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease.

Authors:  Michael Eliasziw; James Kennedy; Michael D Hill; Alastair M Buchan; Henry J M Barnett
Journal:  CMAJ       Date:  2004-03-30       Impact factor: 8.262

7.  Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.

Authors:  Pierre Amarenco; Oscar Benavente; Larry B Goldstein; Alfred Callahan; Henrik Sillesen; Michael G Hennerici; Steve Gilbert; Amy E Rudolph; Lisa Simunovic; Justin A Zivin; K Michael A Welch
Journal:  Stroke       Date:  2009-02-19       Impact factor: 7.914

8.  Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Authors:  Henrik Sillesen; Pierre Amarenco; Michael G Hennerici; Alfred Callahan; Larry B Goldstein; Justin Zivin; Michael Messig; K Michael Welch
Journal:  Stroke       Date:  2008-10-09       Impact factor: 7.914

Review 9.  Effective stroke prevention in patients with symptomatic carotid stenosis.

Authors:  Peter M Rothwell
Journal:  Cerebrovasc Dis       Date:  2004       Impact factor: 2.762

10.  Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA.

Authors:  Brett L Cucchiara; Steve R Messe; Lauren Sansing; Larami MacKenzie; Robert A Taylor; James Pacelli; Qaisar Shah; Scott E Kasner
Journal:  Stroke       Date:  2009-05-21       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.